bis(azetidin-1-yl-thiocarbonyl)disulfide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: bis(azetidin-1-yl-thiocarbonyl)disulfide
• 英文别名: Azetidine-1-carbothioylsulfanyl azetidine-1-carbodithioate
• 化学式: C₈H₁₂N₂S₄
• 分子量: 264.461
• InChiKey: XULYUMHEZZIICL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  121
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  烯丙硫醇 、 bis(azetidin-1-yl-thiocarbonyl)disulfide 以 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成
  参考文献：
  名称：

  [EN] ALLICIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREFOR
  [FR] DÉRIVÉ D'ALLICINE, PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 大蒜素类衍生物及其制备方法和应用

  摘要：

  涉及结构如式I所示的大蒜素类衍生物及其制备方法和应用，其中，R1、R2分别为1~4个碳的烷基、环烷基、萘环、苯基或芳杂环。对现有杀菌剂产生耐药性的病菌，可以采用所述大蒜素衍生物。所述大蒜素衍生物抗菌活性强，抗菌谱更广，针对某些病菌，能达到比现有的健达或大蒜素更好的效果。其合成方法操作简单，反应条件温和，适合工业化生产要求，可用于制备农用杀菌剂。

  公开号：

  WO2022156827A1
• 作为产物：
  描述：

  在 硫酸 、 双氧水 作用下， 以 水 为溶剂， 反应 0.25h， 生成 bis(azetidin-1-yl-thiocarbonyl)disulfide
  参考文献：
  名称：

  [EN] ALLICIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREFOR
  [FR] DÉRIVÉ D'ALLICINE, PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 大蒜素类衍生物及其制备方法和应用

  摘要：

  涉及结构如式I所示的大蒜素类衍生物及其制备方法和应用，其中，R1、R2分别为1~4个碳的烷基、环烷基、萘环、苯基或芳杂环。对现有杀菌剂产生耐药性的病菌，可以采用所述大蒜素衍生物。所述大蒜素衍生物抗菌活性强，抗菌谱更广，针对某些病菌，能达到比现有的健达或大蒜素更好的效果。其合成方法操作简单，反应条件温和，适合工业化生产要求，可用于制备农用杀菌剂。

  公开号：

  WO2022156827A1

文献信息

• Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes
  作者：Yi-xiang Xu、Yun-yuan Huang、Rong-rong Song、Yan-liang Ren、Xin Chen、Chao Zhang、Fei Mao、Xiao-kang Li、Jin Zhu、Shuai-shuai Ni、Jian Wan、Jian Li

  DOI：10.1016/j.ejmech.2020.112500

  日期：2020.10

  Fructose-1,6-bisphosphatase (FBPase), as a key rate-limiting enzyme in the gluconeogenesis (GNG) pathway, represents a practical therapeutic strategy for type 2 diabetes (T2D). Our previous work first identified cysteine residue 128 (C128) was an important allosteric site in the structure of FBPase, while pharmacologically targeting C128 attenuated the catalytic ability of FBPase. Herein, ten approved cysteine covalent drugs were selected for exploring FBPase inhibitory activities, and the alcohol deterrent disulfiram displayed superior inhibitory efficacy among those drugs. Based on the structure of lead compound disulfiram, 58 disulfide-derived compounds were designed and synthesized for investigating FBPase inhibitory activities. Optimal compound 3a exhibited significant FBPase inhibition and glucose-lowering efficacy in vitro and in vivo. Furthermore, 3a covalently modified the C128 site, and then regulated the N125-S124-S123 allosteric pathway of FBPase in mechanism. In summary, 3a has the potential to be a novel FBPase inhibitor for T2D therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.
• Soft tissue implants and drug combination compositions, and use thereof
  申请人：Hunter L. William

  公开号：US20070196421A1

  公开（公告）日：2007-08-23

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring drug combination in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
• Anti-scarring drug combinations and use thereof
  申请人：Hunter L. William

  公开号：US20070208134A1

  公开（公告）日：2007-09-06

  The present invention provides devices or implants that comprise anti-scarring drug combinations, methods or making such devices or implants, and methods of inhibiting fibrosis between the devices or implants and tissue surrounding the devices or implants. The present invention also provides compositions that comprise anti-fibrotic drug combinations, and their uses in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
• Implantable sensors, implantable pumps and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070197957A1

  公开（公告）日：2007-08-23

  Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent or a composition that comprises an anti-scarring agent to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
• Electrical devices and anti-scarring drug combinations
  申请人：Hunter L. William

  公开号：US20070198063A1

  公开（公告）日：2007-08-23

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring drug combination or a composition that comprises an anti-scarring drug combination to inhibit scarring that may otherwise occur when the devices are implanted within an animal.